Anygen

Gwangju, South Korea Founded: 2000 • Age: 26 yrs Listed Acquired By HLB
Peptide API and drug developer for cancer pain disorders

About Anygen

Anygen is a publicly listed company based in Gwangju (South Korea) founded in 2000, and was acquired by HLB in March 2025. Peptide API and drug developer for cancer pain disorders. The company has 83 employees. Its chief executive, as recorded, is Jae Kim. Its focus areas include Diversified Pharmaceuticals.

Company details

Founded in 2000 and based in Gwangju, South Korea, operations center on the biotech sector with GMP and non-GMP production of custom, generic, and catalog peptides. Services are delivered via the Nano-Bio Research center. Three drug candidates are under development in the GIST unit: an anti-cancer agent targeting head and neck cancers, a peptide-based treatment for neuropathic pain, and an oral delivery platform. Licensing is anticipated after preclinical trials.

  • Headquarters Gwangju, South Korea
  • Employees 83
  • Stage Acquired
  • Sectors
    Healthcare
  • Website anygen.com
  • Acquired by HLB (Mar 2025)
  • Legal Name Hlb Pep Co. Ltd.
Key Metrics
  • Annual Revenue
    $3.43 M (USD)
    -20.34
    as on Dec 31, 2025
  • Net Profit
    -$444.86 K (USD)
    90.54
    as on Dec 31, 2025
  • EBITDA
    -$3.47 M (USD)
    -70.06
    as on Dec 31, 2025
  • Investors
    HLB

    & 1 more

  • Employee Count
    83
  • Acquired by
    HLB

    (Mar 2025)

Funding Insights of Anygen

  • Total Rounds 1
  • Investors Count 1

All 1 funding rounds of Anygen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jun 2014Unspecified––
Valuation history

2 investors in total: 2 institutional.

Investors in Anygen

Anygen has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include HLB and Solidus Investment.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
solidusvc.com
Marine composite materials are manufactured for industry applications.
1985hlbkorea.comUlsan, South Korea
Premium access

Investor details for Anygen

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Anygen

1 people are tracked at Anygen (1 in leadership); the tracked headcount is 83.

NameRoleGroup
Jae Kim
CEOLeadership
Premium access

Complete people profiles for Anygen

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Anygen

Anygen is a publicly listed company on the KRX with ticker symbol 196300 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date07 Dec 2016
  • Listed onKRX: 196300
  • Listed entityHLB Pep Co. Ltd.
  • Exchange sectorHealth technology
  • ISINKR7196300008
  • Share price4,370.00 KRW (-4.48% on the day) · 2026-10-14
  • Market capitalisation43,434,807,658.00 KRW
  • EPS (diluted, trailing year)-342.59 KRW
  • Volume (last session)12,109

Financials of Anygen

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
20254.96B KRW-642.5M KRW-5.01B KRW
20246.23B KRW-6.79B KRW-2.95B KRW
20235.61B KRW-9.08B KRW-3.85B KRW
20228.66B KRW-6.20B KRW-1.38B KRW
202110.27B KRW-1.69B KRW2.35B KRW
Premium access

Detailed financial statements for Anygen

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of Anygen

4 dated milestones of Anygen across 25 years, from founding to its latest funding, stage changes and deals.

  1. Founded Anygen is founded.
  2. Funding First funding round.
  3. IPO Lists on the stock exchange (IPO).
  4. Exit Acquired by HLB.

Web traffic of Anygen

Websites that share an audience with Anygen (anygen.com).

Similar websites

Websites whose visitors overlap most with Anygen. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
anyzenkorea.com
anyzenkorea.com
100%
#5,970,879–
newsmac.co.kr
newsmac.co.kr
79%
#1,822,082–
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Anygen

Premium access

Complete news archive for Anygen

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Anygen

Anygen was founded in 2000 and raised its 1st funding round 14 years after it was founded.

Anygen is headquartered in Gwangju, South Korea.

Jae Kim is the CEO of Anygen, as recorded in our data.

Anygen has 83 employees.

Annual revenue of Anygen is $3.43M as on Dec 31, 2025.

Founded in 2000 and based in Gwangju, South Korea, operations center on the biotech sector with GMP and non-GMP production of custom, generic, and catalog peptides. Services are delivered via the Nano-Bio Research center. Three drug candidates are under development in the GIST unit: an anti-cancer agent targeting head and neck cancers, a peptide-based treatment for neuropathic pain, and an oral delivery platform. Licensing is anticipated after preclinical trials.

Yes, Anygen is publicly traded on KRX under the ticker symbol 196300.

Anygen has 2 investors. Key investors include HLB, and Solidus Investment.

Yes. Anygen was acquired by HLB in March 2025.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available